echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Oncotarget: The production of a new microRNA or prostetin E2 that can target lung cancer cells is expected to help treat lung cancer!

    Oncotarget: The production of a new microRNA or prostetin E2 that can target lung cancer cells is expected to help treat lung cancer!

    • Last Update: 2020-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    October 15, 2020 // -- In a recent study published in the international journal Oncotarget, scientists from rutgers' Institute of Biomedical and Health Sciences and others found that high levels of miR-708 expression were directly related to survival rates in patients with pulmonary squamous cell carcinoma, and that miR-708 inhibits the production of PGE2 by inhibiting expressions of COX-2 and mPGES-1 in lung cancer cells.
    addition, the researchers found that miR-708 reduced the proliferation, survival and migration of lung cancer cells, thanks in part to the inhibition of mir-708 on PGE2 signals; 708 targets and regulators that regulate miR-708 expression in lung cancer, the results show that the imbalance of miR-708 expression may promote the accelerated production of PGE2, which will enhance the production of lung cancer cell cluster tumor esope.
    Photo Source: Diffy to Carol S. Lutz - lutzcs@njms.rutgers.edu Researcher Carol S. Lutz says lung cancer is the most common type of cancer, with more than 2.09 million lung cancer patients worldwide in 2018 and, more importantly, lung cancer being the most deadly type of cancer in the global population, with more than 1.79 million lung cancer-related deaths in 2018.
    Lung cancer is a collection of many different subtypes of cancer, of which non-small cell lung cancer accounts for 85% of all lung tumors, miR-708 also indirectly regulates the expression of genes involved in processes such as PI3K signaling, cell cycle progression, epithal-interstitial charge transformation, and dry expression of cancer cells.
    the study, researchers aimed to parse the new miR-708 target and whether miR-708 could act as a cancer-causing or tumor-heterogeneous mi-RNA molecule in lung cancer.
    later researchers will also delve into the key role miR-708 plays in lung cancer, which, along with previous research data, highlights the potential value of miR-708 in lung cancer diagnosis and potential therapeutic interventions, especially for lung squamous cell carcinoma.
    researchers said the study revealed that miR-708 inhibits the new tumor suppression function produced by cancer-causing PGE2 by targeting the expression of COX-2 and mPGES-1. The 708 target, the regulation of miR-708 expression of the regulator is very important, in addition, the study also pointed out that later scientists also need to deeply understand the biological characteristics of lung cancer, so as to help improve the diagnosis and treatment of lung cancer, and ultimately increase the quality of life of lung cancer patients and treatment prognosis.
    original source: Nicholas J. Monteleone and Carol S. Lutz. Monteleone et al, miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells, Oncotarget (2020). DOI: 10.18632/oncotarget.27614.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.